ClinicalTrials.gg
RecruitingNCT07618117RESTUpdated Nov 5, 2026

Improving Sleep Health and Circadian Timing to Support Cardiometabolic Health in Adolescents

An interventional study of Circadian/Sleep (C/S) in Overweight Adolescents, Sleep and Insulin Sensitivity, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 14 Years to 19 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 5, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
14 Years to 19 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Insulin Resistance by University of Colorado, Denver — 5 open to participants now, 7 under way, none of them phase 3. Insulin Resistance · University of Colorado, Denver.

Planned enrollment
7th of 15
60 · median 60
Started
2026
with 1 other
No phase
9 of 24
3 open now
Registered
24th of 24
by date

Among the 24 studies in Insulin Resistance by University of Colorado, Denver, this one is the 7th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2026, is one of 9 with no phase, and was the 24th registered.

Insulin Resistance

2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

5 of the 24 studies in Insulin Resistance by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.

This study: 14 Years to 19 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Insulin Resistance by University of Colorado, Denver, or all of them as a file.
02

Study summary

Many teenagers get too little and late timed sleep. High body weight and diabetes are increasing in teenagers as well. This study plans to learn more about whether improving sleep habits can help improve how the body regulates blood sugar and energy use in teenagers who have higher body weight. To answer this question, the investigators plan to enroll teenagers who get \<7 hours of sleep on school nights and measure changes in blood sugars and energy use after two weeks of typical sleep (sleeping on their normal school schedule) and two weeks of a sleep intervention that includes spending longer time in bed at night, melatonin, and morning light.

03

Conditions studied

  • Overweight Adolescents
  • Sleep
  • Insulin Sensitivity

Browse trials for

04

Who can participate

Ages eligible
14 Years to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. High school students between 14-19 years
  2. Overweight/obesity ( >85% for age and sex)
  3. Have habitually insufficient sleep, defined as ≤ 7 hours per night on school days
  4. Habitually inactive (≤ 3 h of physical activity reported per week)
  5. Tanner stage 4 or 5, based on breast development for girls and testicular size for boys.

Exclusion criteria

Exclusion Criteria:

  1. Reported diagnosis of sleep disorder (e.g., insomnia, obstructive sleep apnea)
  2. Medical comorbidities that impact sleep or insulin sensitivity (e.g., diabetes [based on history or screening ])
  3. Regular use of medications affecting sleep or insulin sensitivity (e.g., stimulants, sleep aids, systemic , insulin sensitizers, GLP-1 agonists)
  4. IQ\<70 or severe mental illness that may impact sleep or study participation (e.g., schizophrenia), eating disorder, or active suicidal ideation
  5. Schedules that would preclude participants from adhering to the sleep schedules (e.g., night-shift employment)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • No intervention
    Typical Sleep

    Habitual sleep schedule

  • Experimental
    Circadian/Sleep (C/S) Condition

    1h additional time in bed, melatonin 2h before bedtime, and 30 minutes bright light after waking

    Behavioral: Circadian/Sleep (C/S)

Interventions

  • BehavioralCircadian/Sleep (C/S)

    1h additional time in bed, melatonin 2h before bedtime, and 30 minutes bright light after waking

06

What researchers measure

Primary outcomes

  1. Insulin sensitivity

    Matsuda Index will be calculated from a mixed meal tolerance test (MMTT); higher values indicate better insulin sensitivity.

    Time frame: Assessed at 2 weeks following each condition

Secondary outcomes

  1. Total daily energy expenditure (TDEE)

    Assessed with doubly labeled water. Higher values indicate greater energy expenditure

    Time frame: Assessed for two weeks during each condition

  2. Average daily caloric intake (kcal/day)

    Calculated from photographic diet diaries. Higher kcal indicates greater caloric intake.

    Time frame: Measured for 3 days during each condition

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data obtained through this study may be provided to qualified researchers with academic interests. Data shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.

Access criteria: Access to study IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact clinicalresearchsupportcenter@ucdenver.edu.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jun 2030, 43 months after the start.

Of 715 non-industry interventional studies with no phase under Insulin Resistance, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 43 months is above that.

Counting every sponsor, half of 755 studies reached it within 21 months; a quarter within 9 and three quarters within 40.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
Jun 1, 2026
StartActual
Oct 20, 2026was Aug 2026
Primary completionEst.
Jun 15, 2030
CompletionEst.
Aug 30, 2030
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
1 site added — first site in United States
Show site
  • Children's Hospital Colorado · Aurora, United States
Nov 5, 2026
Start date
Aug 25, 2026→Oct 20, 2026 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Children's Hospital Colorado · Aurora, United States
    Start date Aug 25, 2026→Oct 20, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07618117
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Oct 20, 2026
Primary completion
Jun 15, 2030 (estimated)
Completion
Aug 30, 2030 (estimated)
Last update
Nov 5, 2026

Study contacts

Stacey L Simon, PhD
Contact
stacey.simon@childrenscolorado.org
720-777-5681
Angel Arias, BS
Contact
angel.arias@childrenscolorado.org
720-777-3491
Stacey L Simon
principal investigator · University of Colorado, Denver

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion